(Q28215446)

2

0 references

Lavern Vercaigne

3

0 references

Andrew Walkty

4

0 references

Alfred S Gin

5

0 references

John Embil

6

0 references

Heather Smith

7

0 references

Daryl J Hoban

In vitro activity of PD 127,391, an enhanced-spectrum quinolone

8

0 references

language of work or name

English

0 references

publication date

2002

0 references

published in

Drugs

0 references

volume

62

0 references

issue

1

0 references

page(s)

13-59

0 references

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics and inflammatory fluid penetration of sparfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics of sparfloxacin in patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Safety of trovafloxacin in treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200262010-00002

Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers

21 January 2018

1 reference

12 December 2020

In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.

1 reference

12 December 2020

Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997)

1 reference

12 December 2020

Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects

1 reference

12 December 2020

Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

1 reference

12 December 2020

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

1 reference

12 December 2020

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group

1 reference

12 December 2020

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group

1 reference

12 December 2020

Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

1 reference

12 December 2020

Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio

1 reference

12 December 2020

In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

12 December 2020

In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones

1 reference

12 December 2020

Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria

1 reference

12 December 2020

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect

1 reference

12 December 2020

Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers

1 reference

12 December 2020

Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.

1 reference

12 December 2020

Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates

1 reference

12 December 2020

Torsades de pointe probably related to sparfloxacin

1 reference

12 December 2020

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

1 reference

12 December 2020

Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction

1 reference

12 December 2020

In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

1 reference

12 December 2020

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

12 December 2020

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones

1 reference

12 December 2020

Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis

1 reference

12 December 2020

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review

1 reference

12 December 2020

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

1 reference

12 December 2020

Ciprofloxacin-induced cutaneous vasculitis

1 reference

12 December 2020

Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model

1 reference

12 December 2020

Quinolones in children. Are concerns over arthropathy justified?

1 reference

12 December 2020

In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae

1 reference

12 December 2020

The chemistry and biological profile of trovafloxacin

1 reference

12 December 2020

Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.

1 reference

12 December 2020

Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group

1 reference

12 December 2020

Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.

1 reference

12 December 2020

Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase

1 reference

12 December 2020

Quinolone mode of action

1 reference

12 December 2020

Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model

1 reference

12 December 2020

In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates

1 reference

12 December 2020

Chemical evolution of the fluoroquinolone antimicrobial agents

1 reference

12 December 2020

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998

1 reference

12 December 2020

In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

1 reference

12 December 2020

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses

1 reference

12 December 2020

Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of grepafloxacin

1 reference

12 December 2020

In vitro activity of gemifloxacin (SB 265805) against anaerobes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

1 reference

12 December 2020

Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci

1 reference

12 December 2020

Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones

1 reference

12 December 2020

Biology of bacterial deoxyribonucleic acid topoisomerases

1 reference

12 December 2020

Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae

1 reference

12 December 2020

Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci

1 reference

12 December 2020

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

The concentrations of clinafloxacin in alveolar macrophages, epithelial lining fluid, bronchial mucosa and serum after administration of single 200 mg oral doses to patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Clinical pharmacokinetics of ciprofloxacin

1 reference

12 December 2020

In vitro activity of trovafloxacin against Chlamydia pneumoniae

1 reference

12 December 2020

Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids

1 reference

12 December 2020

Pharmacodynamic factors of antibiotic efficacy

1 reference

12 December 2020

Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia

1 reference

12 December 2020

Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes

1 reference

12 December 2020

QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin

1 reference

12 December 2020

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

12 December 2020

Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium

1 reference

12 December 2020

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

12 December 2020

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

12 December 2020

Oral bioavailability of trovafloxacin with and without food in healthy volunteers.

1 reference

12 December 2020

Gatifloxacin and moxifloxacin: two new fluoroquinolones

1 reference

12 December 2020

Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers

1 reference

12 December 2020

Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.

1 reference

12 December 2020

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone

1 reference

12 December 2020

Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones

1 reference

12 December 2020

Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis

1 reference

12 December 2020

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

12 December 2020

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

1 reference

12 December 2020

Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones

1 reference

12 December 2020

Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study

1 reference

12 December 2020

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

1 reference

12 December 2020

Kinetics of antimicrobial activity

1 reference

12 December 2020

1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS.

1 reference

12 December 2020

Effects of antacid on absorption and excretion of new quinolones

1 reference

12 December 2020

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

12 December 2020

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

12 December 2020

Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.

1 reference

12 December 2020

In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.

1 reference

12 December 2020

In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391

1 reference

12 December 2020

Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.

1 reference

12 December 2020

In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.

1 reference

12 December 2020

Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin

1 reference

12 December 2020

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

12 December 2020

Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia

1 reference

12 December 2020

Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection

1 reference

12 December 2020

Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents

1 reference

12 December 2020

Safety and efficacy of ciprofloxacin in paediatric patients--review

1 reference

12 December 2020

Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

12 December 2020

In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs

1 reference

12 December 2020

The post-antibiotic effect

1 reference

12 December 2020

The clinical pharmacokinetics of levofloxacin

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.

1 reference

12 December 2020

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis

1 reference

12 December 2020

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines

1 reference

12 December 2020

Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers

1 reference

12 December 2020

A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis

1 reference

12 December 2020

Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.

1 reference

12 December 2020

(Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents

1 reference

12 December 2020

Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

1 reference

12 December 2020

Selection of quinolone-resistant mutants of Haemophilus influenzae and Streptococcus pneumoniae.

1 reference

12 December 2020

Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety

1 reference

12 December 2020

Antipneumococcal activities of gemifloxacin compared to those of nine other agents

1 reference

12 December 2020

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

1 reference

12 December 2020

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects

1 reference

12 December 2020

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

1 reference

12 December 2020

Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

1 reference

12 December 2020

Levofloxacin does not alter cyclosporine disposition

1 reference

12 December 2020

In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

1 reference

12 December 2020

Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults

1 reference

12 December 2020

Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998

1 reference

12 December 2020

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

1 reference

12 December 2020

Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin

1 reference

12 December 2020

Trovafloxacin neurotoxicity.

1 reference

12 December 2020

Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates

1 reference

12 December 2020

The post-antibiotic sub-MIC effect in vitro and in vivo

1 reference

12 December 2020

In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance

1 reference

12 December 2020

Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes.

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of AM-1155 in the fields of obstetrics and gynecology

1 reference

12 December 2020

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

1 reference

12 December 2020

The new fluoroquinolones: A critical review

1 reference

12 December 2020

Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin

1 reference

12 December 2020

Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.

1 reference

12 December 2020

Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria

1 reference

12 December 2020

Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests

1 reference

12 December 2020

Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg

1 reference

12 December 2020

In vitro activities of ketolides HMR 3647 [correction of HRM 3647] and HMR 3004 [correction of HRM 3004], levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis

1 reference

12 December 2020

New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins

1 reference

12 December 2020

Pharmacokinetics and metabolism of single oral doses of trovafloxacin

1 reference

12 December 2020

Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate

1 reference

12 December 2020

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin

1 reference

12 December 2020

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

12 December 2020

In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes

1 reference

12 December 2020

Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes

1 reference

12 December 2020

In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone

1 reference

12 December 2020

The future of the quinolones

1 reference

12 December 2020

Fluoroquinolone antimicrobial agents

1 reference

12 December 2020

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

1 reference

12 December 2020

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

1 reference

12 December 2020

Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.

1 reference

12 December 2020

Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions

1 reference

12 December 2020

Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia

1 reference

12 December 2020

Safety profile of grepafloxacin compared with other fluoroquinolones

1 reference

12 December 2020

Photosensitivity associated with antibacterial agents

1 reference

12 December 2020

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

12 December 2020

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone

1 reference

12 December 2020

Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia

1 reference

12 December 2020

In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas

1 reference

12 December 2020

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections

1 reference

12 December 2020

Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season

1 reference

12 December 2020

Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones.

1 reference

12 December 2020

In vitro activity of levofloxacin against gram-positive bacteria

1 reference

12 December 2020

Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms

1 reference

12 December 2020

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci

1 reference

12 December 2020

The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone

1 reference

12 December 2020

Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections

1 reference

12 December 2020

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

12 December 2020

In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.

1 reference

12 December 2020

ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae

1 reference

12 December 2020

Susceptibility of penicillin-susceptible and -resistant pneumococci to CFC-222, a new fluoroquinolone

1 reference

12 December 2020

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents

1 reference

12 December 2020

In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.

1 reference

12 December 2020

In vitro activity of HSR-903, a new quinolone

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Su

1 reference

12 December 2020

Comparative in vitro activity of gemifloxacin.

1 reference

12 December 2020

Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains

1 reference

12 December 2020

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens

1 reference

12 December 2020

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

12 December 2020

A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects

1 reference

12 December 2020

Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

1 reference

12 December 2020

Quinolone antimicrobial agents and theophylline

1 reference

12 December 2020

Susceptibility of Moraxella catarrhalis to 21 antimicrobial drugs: validity of current NCCLS criteria for the interpretation of agar disk diffusion antibiograms

1 reference

12 December 2020

Safety of trovafloxacin in treatment of lower respiratory tract infections

1 reference

12 December 2020

Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics

1 reference

12 December 2020

In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

12 December 2020

In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.

1 reference

12 December 2020

New topoisomerase essential for chromosome segregation in E. coli

1 reference

12 December 2020

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

12 December 2020

Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

1 reference

12 December 2020

Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli

1 reference

12 December 2020

In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

1 reference

12 December 2020

Levofloxacin in the treatment of community acquired pneumonia

1 reference

12 December 2020

Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis

1 reference

12 December 2020

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone

1 reference

12 December 2020

Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

12 December 2020

Classification and structure-activity relationships of fluoroquinolones

1 reference

12 December 2020

Quinolone-induced QT interval prolongation: a not-so-unexpected class effect

1 reference

12 December 2020

The activity of grepafloxacin against respiratory pathogens in the UK.

1 reference

12 December 2020

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones

1 reference

12 December 2020

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae

1 reference

12 December 2020

Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp

1 reference

12 December 2020

Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents

1 reference

12 December 2020

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

1 reference

12 December 2020

The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects

1 reference

12 December 2020

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections

1 reference

12 December 2020

Mechanism of action of quinolones against Escherichia coli DNA gyrase

1 reference

12 December 2020

Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones

1 reference

12 December 2020

Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin

1 reference

12 December 2020

Quinolone antimicrobial agents: mechanism of action and resistance development

1 reference

12 December 2020

In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia

1 reference

12 December 2020

Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers

1 reference

12 December 2020

In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.

1 reference

12 December 2020

Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition

1 reference

12 December 2020

In vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria

1 reference

12 December 2020

Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases

1 reference

12 December 2020

Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.

1 reference

12 December 2020

DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.

1 reference

12 December 2020

The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.

1 reference

12 December 2020

Age and gender effects on the pharmacokinetics of gatifloxacin.

1 reference

12 December 2020

In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers

1 reference

12 December 2020

Trovafloxacin-induced acute hepatitis

1 reference

12 December 2020

Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages

1 reference

12 December 2020

In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria.

1 reference

12 December 2020

Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA

1 reference

12 December 2020

Fluoroquinolone antimicrobial agents

1 reference

12 December 2020

Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro

1 reference

12 December 2020

Fluoroquinolones: interaction profile during enteral absorption.

1 reference

12 December 2020

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

1 reference

12 December 2020

In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci

1 reference

12 December 2020

Effect of food and gastric pH on the bioavailability of grepafloxacin.

1 reference

12 December 2020

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

1 reference

12 December 2020

Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies

1 reference

12 December 2020

In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood

1 reference

12 December 2020

In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

1 reference

12 December 2020

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

1 reference

12 December 2020

Clinical pharmacokinetics of sparfloxacin

1 reference

12 December 2020

Safety profile of sparfloxacin in the treatment of respiratory tract infections

1 reference

12 December 2020

Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.

1 reference

12 December 2020

In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci

1 reference

12 December 2020

Susceptibility of Legionella species to five antibiotics and development of resistance by exposure to erythromycin, ciprofloxacin, and rifampicin

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones

1 reference

12 December 2020

Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.

1 reference

12 December 2020

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

1 reference

12 December 2020

Role of the new quinolones in pediatric practice.

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

1 reference

12 December 2020

Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

Trends in bacterial resistance to fluoroquinolones

1 reference

12 December 2020

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

1 reference

12 December 2020

Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.

1 reference

12 December 2020

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability

1 reference

12 December 2020

Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates

1 reference

12 December 2020

Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection

1 reference

12 December 2020

Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study

1 reference

12 December 2020

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

1 reference

12 December 2020

Penetration of moxifloxacin into peripheral compartments in humans.

1 reference

12 December 2020

Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997

1 reference

12 December 2020

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods

1 reference

12 December 2020

Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.

1 reference

12 December 2020

The cost of treating community-acquired pneumonia.

1 reference

12 December 2020

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates

1 reference

12 December 2020

Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms

1 reference

12 December 2020

Ciprofloxacin-warfarin coagulopathy: a case series

1 reference

12 December 2020

Multidrug resistance among Streptococcus pneumoniae isolated at a university hospital in eastern Tennessee

1 reference

12 December 2020

Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae

1 reference

12 December 2020

Antibacterial properties of AM-1155, a new 8-methoxy quinolone.

1 reference

12 December 2020

Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers

1 reference

12 December 2020

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

1 reference

12 December 2020

Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.

1 reference

12 December 2020

1 reference

12 December 2020

Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating from 20 European university hospitals. SENTRY Participants Group

1 reference

12 December 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

12 December 2020

Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.

1 reference

12 December 2020

Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters

1 reference

12 December 2020

Growth and development in preterm infants receiving fluoroquinolones.

1 reference

12 December 2020

Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

1 reference

12 December 2020

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

1 reference

12 December 2020

Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

1 reference

12 December 2020

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin

1 reference

12 December 2020

Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

1 reference

12 December 2020

Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers

1 reference

12 December 2020

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

1 reference

12 December 2020

A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

1 reference

12 December 2020

1 reference

12 December 2020

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

1 reference

12 December 2020

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

12 December 2020

Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group

1 reference

12 December 2020

Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group

1 reference

12 December 2020

Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.

1 reference

12 December 2020

Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin

1 reference

12 December 2020

Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan

1 reference

12 December 2020

A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose

1 reference

12 December 2020

Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study

1 reference

12 December 2020

Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males

1 reference

12 December 2020

A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.

1 reference

12 December 2020

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

12 December 2020

1 reference

12 December 2020